Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
Status:
Terminated
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if combination Erlotinib, Cisplatin/Carboplatin,
and Paclitaxel are effective first line treatment for metastatic, recurrent and persistent
squamous cell carcinoma of the head and neck.